Overexpression of p53 protein is a marker of poor prognosis in Mexican women with breast cancer
Autor: | José Guadalupe Muñoz-Camacho, Jisela Dimas-González, Alfredo Lagunas-Martínez, José Díaz-Chávez, Marco Antonio Terán-Porcayo, Vilma Maldonado-Lagunas, María Eugenia López-Arellano |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Adult Cancer Research Triple Negative Breast Neoplasms Proximity ligation assay Biology 03 medical and health sciences 0302 clinical medicine Breast cancer Antigens Neoplasm Gene duplication medicine Biomarkers Tumor Humans Mexico Aged Regulation of gene expression Aged 80 and over Oncogene Gene Amplification Cancer General Medicine Sequence Analysis DNA Middle Aged medicine.disease Prognosis Molecular medicine Survival Analysis Up-Regulation DNA-Binding Proteins Gene Expression Regulation Neoplastic 030104 developmental biology Real-time polymerase chain reaction DNA Topoisomerases Type II Oncology 030220 oncology & carcinogenesis Cancer research Female Tumor Suppressor Protein p53 |
Zdroj: | Oncology reports. 37(5) |
ISSN: | 1791-2431 |
Popis: | Breast cancer (BC) is a disease with different clinical, histological and molecular characteristics, frequently presenting mutated tumour-suppressing genes and oncogenes. P53 is a known tumour suppressor that is often mutated in BC; several mutations in p53 inhibit its role as a transcriptional repressor of several oncogenes. Topoisomerase 2α (TOP2α) is a gene target of p53, and it is also a known target for anthracyclines. The aim of the present study, was to analyse the genetic alterations of p53 and TOP2α genes and their levels of protein expression, as well as their association with survival in Mexican women with BC. A total of 102 biopsies were collected (tumour and adjacent tissues) from patients with BC. To identify point mutations and deletions in the p53 gene, the Sanger sequencing method was carried out. Deletions or amplifications for TOP2α gene were determined using quantitative polymerase chain reaction (qPCR). In addition, the expression of the TOP2α and p53 proteins was evaluated by western blotting. Furthermore, p53 protein expression was analysed by proximity ligation assay (PLA)-qPCR. Only 28.5% of the patients were found to have triple-negative breast cancer (TNBC); the average age at the time of diagnosis of these patients was 50 years, and Scarff-Bloom-Richardson (SBR) histological grade III (p=0.0089). No differences in point mutations or deletions in p53, and deletions or amplifications as well as protein expression level of TOP2α were observed between patients with TNBC and non-TNBC patients. However, patients with TNBC showed p53 protein overexpression as determined by PLA-qPCR and western blotting (p |
Databáze: | OpenAIRE |
Externí odkaz: |